Breaking News, Trials & Filings

Roche, InterMune Initiate Phase IIb HCV Trial

Roche and InterMune have initiated a Phase IIb study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with Pegasys (pegylated interferon alfa-2a) and Copegus (ribavirin).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche and InterMune have initiated a Phase IIb study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with Pegasys (pegylated interferon alfa-2a) and Copegus (ribavirin). The study will be conducted at 45 sites globally and will further evaluate the safety and efficacy profile of the drug. Approximately 300 treatment-naive patients with chronic HCV genotype 1 infection will participate. The initiation of the Phase IIb trial triggered a $20 million payme...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters